Longenesis and business angels led by Rustam Gilfanov close $1.2 million late seed round - IssueWire
Summary
Longenesis offers three main products: Curator enables such research institutions as hospitals and biobanks to publish anonymized patient records and get requests for cooperation directly from study sponsors. However, the data-enhanced display and accessibility enable third parties to quickly assess if such data is relevant to their research projects and at the same time speed up what was previously a difficult, sluggish, expensive, and time-consuming process. In the EU, the Middle East, and Asia, Longenesis has already implemented its solutions with a variety of governments, biopharmaceutical firms, and academic consortia by offering data curation and patient contact services. LongeVC’s Managing Partner, Garri Zmudze, says: “For any biotech or longevity-focused enterprise, compliant access to clinical data and patient cohorts will remain a critical success component. In the future years, we think, Longenesis has what it takes to become a backbone of compliant biomedical data usage.” Rustam Gilfanov, a business angel and Venture Partner at the LongeVC investment fund, who led the investment round, spoke on the importance of digitalization in biotechnology and medical research: “Biotechnology is quickly evolving nowadays, with formerly totally human-dependent and too laborious procedures becoming digitalized.